Indicators | Dimension | Result | Standard |
---|---|---|---|
Compliance of initial treatment with GESIDA guidelines | Effectiveness | 92.15% | 95% |
Undetectable viral load (<50 copies/ml) at week 48 | Effectiveness | 88.25% | 80% |
Treatment modifications within the first year | Effectiveness | 28.43% | <30% |
Resistance study in virological failures | Effectiveness | 74% | 90% |
Abacavir initiation without HLA-B*5701 screening | Safety | 0% | 0% |
Treatment adherence measure | Follow-up | 54.9% | 95% |
Average annual expenditure per patient | Efficiency | €8,552 | €8,633 |